CMS gives Medicare Advantage rates a 2.48% bump for 2027 plan year in final rule

CMS finalized a 2.48% Medicare Advantage rate increase for the 2027 plan year (vs the 0.09% proposed), equating to roughly $13 billion in additional payments to plans. The bump reflects underlying cost growth, potential effects of 2026 star ratings on bonuses, and a delay to proposed risk-adjustment changes (V28 timing indefinite). Insurers rallied on the news while provider group AMGA called the increase insufficient and warned of likely benefit/plan cuts; CMS emphasized continued oversight of upcoding and other practices to game risk adjustment.

Analysis

The administration’s move reduces an acute near-term shock to MA economics but simultaneously increases the probability of stepped-up downstream enforcement and auditing over the next 12–36 months. Carriers that relied on coding intensity as a durable margin lever will see a softer immediate headwind, but they face asymmetric tail risk from RADV-style clawbacks and targeted audits once CMS pivots from rate-setting to compliance extraction.

A durable implication is a bifurcation between scale/diversified insurers and smaller regional plans: scale players with integrated risk platforms and diversified revenue (care delivery, pharmacy, data analytics) can convert a modest policy reprieve into incremental upside, while single-line MA specialists are most exposed to any retroactive adjustments or renewed parity scrutiny. Expect incremental demand for third-party risk‑adjustment, chart‑review and revenue-cycle services as plans and providers preempt audits; these vendors can capture 100–300bps of operating-margin uplift for clients who successfully migrate chart review burdens off clinicians.

Near-term market moves have likely priced a relief rally; what’s underpriced is the timeline and intensity of enforcement. If CMS follows up with targeted RADV sweeps or tightens allowable diagnosis sources (telehealth exclusions, sampling changes), we could see concentrated P&L volatility across insurer cohorts within 6–18 months, not immediately — making trade sizing and optionality the right levers for positioning.

Key Decisions for Investors

• Long UNH (UnitedHealth) stock, 3–9 month horizon: buy equity to capture a favorable re‑rating toward higher MA visibility and diversified upside. Risk: regulatory headlines and RADV noise could compress multiple by ~8–12% in a downside scenario; reward: 10–20% upside if sentiment stays constructive and enrollment trends hold.
• Long RCM vendor RCM (R1 RCM), 6–12 month horizon: exposure to increased compliance/chart‑review spending as payers and providers shore up documentation. Risk/reward: asymmetric — modest revenue acceleration with 2:1 upside vs downside if CMS reduces allowable chart‑review pathways.
• Pair trade — long HUM (Humana) or ELV (Elevance) vs short HCA (HCA Healthcare), 6–12 months: carriers win on benchmark stability and potential margin tailwinds, hospitals/providers remain vulnerable to reimbursement pressure and narrower networks. Target sizing: 1:1 notional; stop-loss at 8% adverse move; target 15–25% pair dispersion if policy enforcement intensifies.
• Options hedge: buy 4–6 month call spreads on UNH or ELV (buy 5–10% OTM, sell 25–30% OTM) to capture upside from policy clarity while capping premium outlay. This preserves upside capture through the next CMS enforcement-update window while limiting time decay exposure.